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(inappropriately) calibrated using UK social preferences weights.
METHODS: The Franks (2004) and Lawrence (2004) algo-
rithms for computing EQ-5Dindex values from SF-36 responses
were applied to data collected in a UK national population
survey (n ~ 16,000) in which respondents had also completed an
EQ-5D questionnaire. The estimated and observed EQ-5Dindex
scores were computed for 6 major diagnostic groups (respira-
tory, endocrine, circulatory, musculoskeletal, cancer, mental
health). The published US scoring algorithm for EQ-5Dindex was
also applied to these responses. The potential 1-year QALY gains
for each group were estimated using UK population age/sex
norms for EQ-5D, assuming complete remission of current ill-
health condition. RESULTS: Although for some diagnostic
groups mean absolute differences appeared relatively small, 
differences between estimated and observed EQ-5Dindex varied
enormously. QALY gains varied when EQ-5Dindex scores were
replaced by Franks and Lawrence’s scores. The rank order of
these gains was not signiﬁcantly altered when US EQ-5D weights
were used in place of UK social preferences. CONCLUSION:
Conversion models that directly estimate EQ-5Dindex scores are
dangerously vulnerable to the value set used to estimate the
regression model. Models calibrated using UK population pref-
erence weights should only be in extremis and with due care
where domestic national values re unavailable.
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OBJECTIVES: To estimate the prevalence of dementia in the
Indiana Medicaid population and to evaluate how varying the
dementia patient selection criteria used in previous studies affects
prevalence estimates. METHODS: Indiana Medicaid claims data
for the period July 1, 2001 through December 31, 2003 were
analyzed. An expert panel survey also was conducted to assess
speciﬁcity of ICD codes used in previous studies to deﬁne demen-
tia. Prevalence estimates were calculated with varying levels of
each of the selection criteria, i.e., ICD code set, interval of data
examined, and number of occurrences of dementia-related
claims. RESULTS: Prevalence varied greatly across age strata.
The impact of each selection criteria on prevalence estimates was
similar. Depending on selection criteria used, the prevalence of
dementia for individuals 40 years old or older varied from 6%
to 13%, while prevalence for individuals 60 years old or older
varied from 11% to 22%. Using as criteria the occurrence of two
or more dementia-related claims, the expert panel ICD set, and
30 months of data for deﬁning dementia, the prevalence of
dementia in the Indiana Medicaid population was 7.9% for 
individuals 40 years old or older, 11% for individuals 50 years
old or older, and 14% for individuals 60 years old or older.
CONCLUSIONS: Selection criteria used to identify patients with
dementia from medical claims can affect estimates of prevalence
by nearly two-fold. Prevalence of dementia among Indiana Med-
icaid beneﬁciaries age 50 years old or older and among beneﬁ-
ciaries age 60 years old or older was 2.5 to 3.5 times higher than
the reported prevalence from a decade ago in Medicaid popula-
tions of other states, even when the same selection criteria were
used. This analysis provides an ICD code set that can be used in
claims-based work, to identify patients with dementia.
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OBJECTIVE: To systematically evaluate and assess the effec-
tiveness of antidepressants in treating depressed patients after
stroke. METHODS: A systematic review with Meta analysis of
double-blinded randomized clinical trials (RCTs) about the treat-
ment of depression in the patients with stroke. Data were col-
lected from the published RCTs, which indexed in the Medline
from 1960 to 2005. Review was only limited in the English 
articles. Outcome measurements: 1) The proportion of treatment
responders whose depression scores improved by >50% was
compared. 2) The depression rating scores at the beginning,
middle, and end of treatments. RESULTS: A total of 313 patients
from 5 RCTs fulﬁlling the inclusion criteria were identiﬁed for
this study. The percentages of responders in treatment and
control group were 57.9% and 44.4%, respectively (Risk Dif-
ference, RD = 0.17, 95%CI from -0.04 to 0.38, Z = 1.61, P =
0.11). In term of depression scores, prior to any treatments, the
overall depression scores in the patients of treatment groups were
a little bit higher (more depressed) than the patients in the
control groups, but the difference was not statistically signiﬁcant
(Weighted Mean Difference, WMD = 1.01, Z = 1.59, P = 0.11).
After the treatments, patients in the treatment groups became
statistically less depressed than the patients in the control groups
in term of lower depression scores (WMD = -1.88, Z = 2.16, P
= 0.03). In addition, we found that the overall WMD in term of
depression scores between two groups was 0.60 (Z = 0.87, p =
0.39) at the beginning of treatment, and became -1.85 (Z = 2.12,
P = 0.03) in the middle of treatment, then further decreased to
-3.06 (Z = 2.92, p = 0.004) at the end of treatment. CON-
CLUSION: The results indicated that antidepressant treatments
were effective in the patients after stroke in term of reducing the
depression scores and treatment effects were time dependent. In
addition, more efforts should be guaranteed to study the cere-
brovascular effects of antidepressants in patients after stroke.
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OBJECTIVE: To determine time to discontinuation in schizo-
phrenic patients who commence RLAI. METHODS: e-STAR
(electronic-Schizophrenia Treatment Adherence Registry) is an
ongoing international observational study of schizophrenic
patients who commence RLAI. Data collected retrospectively
(12-months) and prospectively (2-years) included: patient 
demographics, medications, hospitalisations, Clinical Global
Impression-Severity (CGI-S), Global Assessment of Functioning
(GAF) and adverse events. A priori statistical analyses using
Kaplan-Meier curves and proportional hazard regression models
included time to discontinuation. RESULTS: Data from 591
patients from 15 hospitals were available for this analysis. The
average age was 36.9 [12.5] years (mean [SD]), duration of
illness was 11.0 [9.3] years, 71% were male. The baseline CGI-
S was 4.5 [1.2] and GAF was 41.8 [14.8]. Ninety-one percent of
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patients were initiated on 25mg of RLAI. At 12-months 63% 
of patients were still on RLAI. The reasons for discontinuation
were lack of response (14%); loss-to-follow-up (10.5%); other
(7.5%); patient or family choice (6%); adverse events (6%); tol-
erability (2%); and adherence (1.5%). Young age at schizophre-
nia onset and suicidal behavior at baseline were signiﬁcant risk
factors for time to discontinuation (p < 0.04). CONCLUSIONS:
The treatment continuation rate with RLAI at 12-months is con-
sistent with the results of Fleischhacker et al (2003), but supe-
rior to oral typical and atypical agents (Lieberman et al, 2005).
Fleischhacker et al (2003); J Clin Psychiatry 64(10):1250–1257.
Lieberman et al (2005); NEJM 353:1209–23.
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OBJECTIVE: To summarize rates of clinical remission and
dropouts/withdrawal due to adverse drug reactions (ADRs) or
lack of efﬁcacy/effectiveness (LoE) of serotonin-norepinephrine
reuptake inhibitors (SNRIs), selective serotonin reuptake inhibi-
tors (SSRIs) and tricyclic antidepressants (TCAs). METHODS:
We searched Medline, Embase, International Pharmaceutical
Abstracts, and The Cochrane International Library from 1980
to 2005 for clinical trials using MeSH terms “serotonin norepi-
nephrine reuptake inhibitors”, “selective serotonin reuptake
inhibitors”, “tricyclic antidepressants”, “major depression”, and
“clinical remission”. Accepted languages were English, French,
German, Portuguese, and Spanish. A meta-analytic approach
was used to synthesize outcome rates from published head-to-
head clinical trials comparing two or more drugs (in therapeutic
doses) from SNRIs, and/or SSRIs, and/or TCAs from 6 to 12
weeks of treatment. Remission was deﬁned as a ﬁnal score = <7
on the Hamilton Depression Rating Scale or = <12 in the 
Montgomery-Asberg Depression Rating Scale. Data were 
combined across arms of individual studies using a random
effects model, producing point estimates with 95% conﬁdence
intervals. RESULTS: Data were gathered from 30 arms of 15
head-to-head trials of 2524 patients. TCAs had the highest
overall remission rate (45.7%), followed by SNRIs (45.0%), and
SSRIs (38.8%) (p > 0.05 for TCAs versus SNRIs; p < 0.001 for
TCAs versus SSRIs; and p < 0.001 for SNRIs versus SSRIs).
When patients were categorized as inpatients (n = 582) and out-
patients (n = 1613), SNRIs had the highest remission rate (52.0%
for 144 inpatients and 49.3% for 559 outpatients). SNRIs had
the lowest overall discontinuation rates (24.3%), followed by
SSRIs (27.1%), and TCAs (34.9%). Rates of discontinuation due
to ADRs and LoE were 9.8% and 5.2% for SNRIs, 7.3% and
7.0% for SSRIs, and 18.9% and 9.1% for TCAs, respectively. 
CONCLUSIONS: SNRIs have the highest efﬁcacy/effectiveness
remission rates (statistically signiﬁcant for inpatients and 
outpatients), and the lowest overall dropout/withdrawal rates 
suggesting clinical superiority for this class in treating major
depressive disorders.
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OBJECTIVE: While SGA therapy has been associated with new-
onset diabetes, the relative risk of the agents and the impact of
possible confounding variables have been questioned. This study
evaluated the impact of dose and treatment indication on the 
relative risk of new-onset diabetes associated with SGA therapy
while controlling for demographic, clinical and medication vari-
ables. METHODS: A retrospective database analysis capturing
electronic medical records for adult Texas Medicaid enrollees
taking antipsychotic monotherapy from January 1997 to 
December 2001, with a maximum follow-up of 12 months was
used. Patients were stratiﬁed according to treatment dose (low,
medium, high) and a hierarchy of mutually exclusive diagnostic
categories: schizophrenia, bipolar disorder, dementia, psychotic
disorder, non-psychotic disorder and no mental health indica-
tion. The incidence of diabetes was examined using multivariate
logistic regression analysis. RESULTS: Data were available for
13,731 patients. At treatment-onset, the prevalence of diabetes
was 16.9%. The mean (SD) dose by indication for the most
prevalent conditions (schizophrenia, bipolar disorder and
dementia, respectively) were as follows: olanzapine (12.04mg
(6.73); 8.91mg (5.78); 4.87mg (3.00)); quetiapine (273.16mg
(203.86); 146.33mg (142.29); 79.59 (82.57)); and risperidone
(3.55mg (2.37); 2.05 (1.76); 1.12 (0.85)). The overall incidence
of diabetes was 2.6%. Multivariate logistic regression analysis
showed no difference in the incidence of diabetes according to
the agent used (p = 0.281). Compared to risperidone, the odds
of new-onset diabetes were 0.879 (95% CI: 0.653 to 1.184) and
0.683 (95% CI: 0.414 to 1.126) for olanzapine and quetiapine,
respectively. Neither treatment indication (p = 0.876) nor
antipsychotic dose (p = 0.274) were associated with the devel-
opment of diabetes. CONCLUSIONS: Results indicate that the
risk of new-onset diabetes does not differ among SGA agents
(i.e., olanzapine, quetiapine and risperidone). While the dose of
antipsychotic prescribed varied signiﬁcantly according to treat-
ment indication and patient age, neither dose nor indication were
associated with the development of diabetes.
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OBJECTIVES: Atypical antipsychotic-induced diabetes has
raised concerns recently, while the extent of atypical 
antipsychotic-induced diabetes mellitus among Asians with
schizophrenia is not well known. This study aims to compare the
association of atypical antipsychotic treatments and diabetes
mellitus with that of haloperidol treatment and diabetes mellitus
among schizophrenic patients in Taiwan. METHODS: Data used
in this study came from Taiwan’s National Health Insurance
claims database for the period 2000–2004. This study identiﬁed
antipsychotic treatment episodes of clozapine, olanzapine,
risperidone, quetiapine, amisulpride, ziprasidone, and haloperi-
